Presentation (CTI)

OBJECTIVES: The aim of this study was to estimate healthcare resource use and treatment costs of the endometrial cancer (EC) from the perspective of the public healthcare system.
METHODS: A Delphi panel including five gynecological oncologists experienced in treating EC within the public healthcare system was conducted. The panel aimed to capture the resources used for diagnosis, monitoring examinations, treatments in 1L and 2L, disease complications, and adverse event management. Treatment costs were estimated using prices from Brazilian public databases for drugs, procedures, and hospitalization, and are reported per patient in BRL.
RESULTS: Non-recurring costs with diagnosis and staging (laboratory tests, imaging, and molecular analysis) totaled BRL 1,386.16. Follow-up costs were higher for advanced diseases, estimated at BRL 1,457.59 for the first three years and BRL 858.83 per year thereafter; for early-stage disease, costs were BRL 1,052.20 during the first three years and BRL 490.80 per year thereafter. In terms of healthcare resource use, advanced stages (III/IV) required significantly longer average stays in healthcare services compared to early stages (I/II), including hospitalization (8 days vs. 4 days) and ICU stays (6 days vs. 4 days).
Advanced stages consistently incurred higher treatment expenditures. The average annual cost per patient was BRL 14,787.29 for stages I/II, rising to BRL 26,150.28 for resected stage III/IV disease. For advanced stage III/IV disease, costs were BRL 63,336.94 for pMMR and BRL 93,120.09 for dMMR patients, respectively.
CONCLUSIONS: Advanced stages (III and IV) incur significantly higher costs to the Brazilian public health system compared with early stages (I and II). These findings underline the importance of early diagnosis and the need to prioritize resource allocation towards effective treatments which may improve clinical outcomes and economic efficiency within the SUS.
Funding: GSK (218936)